Aurinia Pharmaceuticals (AUPH) Common Equity (2017 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Common Equity came in at $1.1 billion in Q1 2026, up 210.3% YoY from $350.2 million in Q1 2025, and up 86.92% on a QoQ basis from $581.3 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Common Equity (2017 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 10 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.
- Quarterly Common Equity rose 210.3% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 210.3% YoY) and the FY2025 annual result came in at $581.3 million, up 54.0% from the prior year.
- Common Equity advanced to $1.1 billion in Q1 2026, from $581.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.1 billion in Q3 2025 to a low of $335.3 million in Q2 2025.
- A 5-year average of $483.1 million and a median of $391.9 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slipped 15.37% — and 2026, when it soared 210.3%.
- Tracing AUPH's Common Equity over 5 years: stood at $405.4 million in 2022, then fell by 6.78% to $378.0 million in 2023, then declined by 0.13% to $377.5 million in 2024, then soared by 54.0% to $581.3 million in 2025, then jumped by 86.92% to $1.1 billion in 2026.
- The last three Common Equity figures came in at $1.1 billion (Q1 2026), $581.3 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 1.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Bn |
| Mar 31, 2026 | 1.09 Bn |
| Dec 31, 2025 | 581.33 Mn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 335.30 Mn |
| Mar 31, 2025 | 350.19 Mn |
| Dec 31, 2024 | 377.48 Mn |
| Sep 30, 2024 | 388.00 Mn |
| Jun 30, 2024 | 364.62 Mn |
| Mar 31, 2024 | 359.48 Mn |
| Dec 31, 2023 | 377.95 Mn |
| Sep 30, 2023 | 391.88 Mn |
| Jun 30, 2023 | 392.29 Mn |
| Mar 31, 2023 | 390.41 Mn |
| Dec 31, 2022 | 405.44 Mn |
| Sep 30, 2022 | 423.43 Mn |
| Jun 30, 2022 | 423.77 Mn |
| Mar 31, 2022 | 448.12 Mn |
| Dec 31, 2021 | 479.09 Mn |
| Sep 30, 2021 | 298.17 Mn |